OncoMatch

OncoMatch/Clinical Trials/NCT06139926

Clinical Study of Dexmedetomidine Administered Intranasally to Relieve Perioperative Anxiety and Depression in Patients With Colorectal Tumors

Is NCT06139926 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Dexmedetomidine administered intranasally for colorectal cancer.

Phase 3RecruitingFirst Affiliated Hospital of Chongqing Medical UniversityNCT06139926Data as of May 2026

Treatment: Dexmedetomidine administered intranasallyCurrently, domestic and international research on dexmedetomidine as well as anxiety and depression is more focused on basic research. In terms of clinical research, dexmedetomidine is more often used in pediatrics, short surgeries, intensive care units, etc., for sedation and analgesia; while less research has been done for the relief of anxiety and depression. At present, on the one hand, the number of oncology patients is on the rise both at home and abroad, and on the other hand, anxiety and depression account for an increasing proportion of healthcare in the world. Tumor patients, as a high prevalence group of anxiety and depression, their prognosis and regression are also more complicated. Therefore, exploring the role of intranasal administration of dexmedetomidine in relieving perioperative anxiety and depression in oncology patients has a very strong practical basis and clinical significance.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Performance status

ASA 2–3

Prior therapy

No prior treatment (treatment-naive required)

Lab requirements

Kidney function

No serious abnormalities of kidney function

Liver function

No serious abnormalities of liver function

Cardiac function

No second or third degree atrioventricular block, severe sinus bradycardia (<50 beats/min), sick sinus node syndrome, congenital heart disease, or other cardiac arrhythmias that severely affect hemodynamic stability

Serious abnormalities of liver or kidney function. Second or third degree atrioventricular block, severe sinus bradycardia (<50 beats/min), sick sinus node syndrome, congenital heart disease, and other cardiac arrhythmias that severely affect hemodynamic stability

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify